What it is
Edaravone, a free-radical scavenger given intravenously, is approved for amyotrophic lateral sclerosis in several countries. This phase 3 trial tested a once-daily oral version (FNP122) against placebo in 302 patients over 48 weeks. Decline on the ALS functional rating scale was -12.6 points on edaravone and -13.4 points on placebo, a difference of 0.78 points that was not statistically significant.
Why it matters
ALS has very few disease-modifying treatments, so an oral drug that worked over a longer period and a broader group than earlier edaravone studies would have mattered. A clearly reported null result is useful in itself: it steers patients and clinicians away from an ineffective option.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underAmyotrophic Lateral Sclerosis Research, Alzheimer's disease research and treatments, Multiple Sclerosis Research Studies